Eton Pharmaceuticals Statistics
Share Statistics
Eton Pharmaceuticals has 26.63M shares outstanding. The number of shares has increased by 3.83% in one year.
| Shares Outstanding | 26.63M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 3.09% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 25.12M |
| Failed to Deliver (FTD) Shares | 266 |
| FTD / Avg. Volume | 0.12% |
Short Selling Information
The latest short interest is 191.94K, so 0.72% of the outstanding shares have been sold short.
| Short Interest | 191.94K |
| Short % of Shares Out | 0.72% |
| Short % of Float | 0.76% |
| Short Ratio (days to cover) | 0.93 |
Valuation Ratios
The PE ratio is -120.01 and the forward PE ratio is 17.3.
| PE Ratio | -120.01 |
| Forward PE | 17.3 |
| PS Ratio | 3.55 |
| Forward PS | 3.6 |
| PB Ratio | 7.26 |
| P/FCF Ratio | 18.6 |
| PEG Ratio | n/a |
Enterprise Valuation
Eton Pharmaceuticals Inc. has an Enterprise Value (EV) of 61.13M.
| EV / Earnings | -65.31 |
| EV / Sales | 1.93 |
| EV / EBITDA | -210.07 |
| EV / EBIT | -51.28 |
| EV / FCF | 10.12 |
Financial Position
The company has a current ratio of 1.65, with a Debt / Equity ratio of 0.35.
| Current Ratio | 1.65 |
| Quick Ratio | 1.6 |
| Debt / Equity | 0.35 |
| Total Debt / Capitalization | 25.79 |
| Cash Flow / Debt | 1.27 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.06% and return on capital (ROIC) is -7.76%.
| Return on Equity (ROE) | -0.06% |
| Return on Assets (ROA) | -0.03% |
| Return on Capital (ROIC) | -7.76% |
| Revenue Per Employee | 1.05M |
| Profits Per Employee | -31.20K |
| Employee Count | 30 |
| Asset Turnover | 1 |
| Inventory Turnover | 11.61 |
Taxes
| Income Tax | 247.00K |
| Effective Tax Rate | -0.36 |
Stock Price Statistics
The stock price has increased by 227.38% in the last 52 weeks. The beta is 1.26, so Eton Pharmaceuticals 's price volatility has been higher than the market average.
| Beta | 1.26 |
| 52-Week Price Change | 227.38% |
| 50-Day Moving Average | 11.62 |
| 200-Day Moving Average | 6.24 |
| Relative Strength Index (RSI) | 56.58 |
| Average Volume (20 Days) | 226.75K |
Income Statement
In the last 12 months, Eton Pharmaceuticals had revenue of 31.64M and earned -936.00K in profits. Earnings per share was -0.04.
| Revenue | 31.64M |
| Gross Profit | 21.06M |
| Operating Income | -1.19M |
| Net Income | -936.00K |
| EBITDA | -291.00K |
| EBIT | -1.19M |
| Earnings Per Share (EPS) | -0.04 |
Balance Sheet
The company has 21.39M in cash and 5.40M in debt, giving a net cash position of 15.99M.
| Cash & Cash Equivalents | 21.39M |
| Total Debt | 5.40M |
| Net Cash | 15.99M |
| Retained Earnings | -104.07M |
| Total Assets | 35.84M |
| Working Capital | 10.02M |
Cash Flow
In the last 12 months, operating cash flow was 6.82M and capital expenditures -775.00K, giving a free cash flow of 6.04M.
| Operating Cash Flow | 6.82M |
| Capital Expenditures | -775.00K |
| Free Cash Flow | 6.04M |
| FCF Per Share | 0.24 |
Margins
Gross margin is 66.56%, with operating and profit margins of -3.77% and -2.96%.
| Gross Margin | 66.56% |
| Operating Margin | -3.77% |
| Pretax Margin | -2.18% |
| Profit Margin | -2.96% |
| EBITDA Margin | -0.92% |
| EBIT Margin | -3.77% |
| FCF Margin | 19.09% |
Dividends & Yields
ETON does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -0.3% |
| FCF Yield | 1.69% |
Analyst Forecast
The average price target for ETON is $18, which is 34.4% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $18 |
| Price Target Difference | 34.4% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
Scores
| Altman Z-Score | 6.42 |
| Piotroski F-Score | 3 |